Brussels, 10/11/2003 (Agence Europe) - The medical and pharmaceutical biotech industry has welcomed the proposed revision of EU pharmaceutical legislation, particularly the plan to protect patents for 10 years (extended by a year in the event of new indications) and keep the centralised procedures for launching products. The criteria determining equivalence between generic drugs and specialities (set out in the Council's common position) will be tightened up in order to ensure patient...